Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2
Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2
MXiPr (Methoxisopropamine, Isopropyloxetamine, Isopropyxetamine) is a recreational designer drug with dissociative effects. It is an arylcyclohexylamine derivative, related to drugs such as ketamine and methoxetamine. It is the N-isopropyl homologue to methoxetamine. Since it hasn’t been extensively studied, the pharmacological effects are unclear, but its effects are reportedly similar to methoxetamine. It was first identified in Slovenia in December 2020,[1] and was made illegal in Hungary in April 2021.
Methoxisopropamine
Forensic labs struggle to differentiate MXiPr from the isomeric MXPr using MS alone. This ≥98% pure hydrochloride reference standard solves this by providing an inverted retention order on biphenyl LC columns-a critical orthogonal identification point. – Enables unambiguous forensic identification vs. MXPr when MS fragmentation patterns overlap. – Delivers a reliable IC50 of 0.661 µM at NMDAR for SAR and dose-response studies. – Ethanol solubility of 20 mg/ml supports concentrated stock preparation without DMSO interference.
See also
Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2, Buy MXiPr Methoxisopropamine Isopropyloxetamine Cas 2666932-55-2
-
MXiPr (Methoxisopropamine, Isopropyloxetamine, Isopropyxetamine) is a recreational designer drug with dissociative effects. It is …
-
Methoxisopropamine (MXiPr) ≥98% – Benchchem
Methoxisopropamine
Technical Parameters
Basic Identity
| Product Name | Methoxisopropamine |
|---|---|
| Molecular Formula | C16H23NO2 |
| Molecular Weight | 261.36 g/mol |
Structural Identifiers
| SMILES | CC(C)NC1(CCCCC1=O)C2=CC(=CC=C2)OC |
|---|---|
| InChI | InChI=1S/C16H23NO2/c1-12(2)17-16(10-5-4-9-15(16)18)13-7-6-8-14(11-13)19-3/h6-8,11-12,17H,4-5,9-10H2,1-3H3 |
| InChIKey | FTQIVDGNGXPEKP-UHFFFAOYSA-N |
Commercial & Availability
| Standard Pack Sizes | 1 mg / 5 mg / 50 mg / Bulk Custom |
|---|---|
| Availability | In Stock |
| Custom Synthesis | Available on request |
Methoxisopropamine (MXiPr) Procurement: Chemical Identity and Classification
Methoxisopropamine (MXiPr) is an arylcyclohexylamine derivative, structurally related to ketamine and methoxetamine [1]. It is formally designated as 2-(isopropylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (C16H23NO2) with a molecular weight of 261.36 g/mol and a calculated XLogP3-AA of 2.7 [2][3]. As a designer dissociative substance, it is primarily used as an analytical reference standard for research and forensic applications, and is often supplied as the hydrochloride salt .
- [1] Methoxisopropamin – Wikipedia. Methoxisopropamin (MXiPr, Isopropyloxetamin, Isopropyxetamin) ist eine Forschungschemikalie mit dissoziativer Wirkung, die wie Ketamin oder Methoxetamin strukturell zur Gruppe der Arylcyclohexylamine zählt. View Source
- [2] PubChem. Methoxisopropamine. Molecular Formula C16H23NO2; Molecular Weight 261.36 g/mol. View Source
- [3] PubChem. Methoxisopropamine. XLogP3-AA 2.7 (Computed by XLogP3 3.0). View Source
Why Generic Substitution of Methoxisopropamine (MXiPr) is Scientifically Invalid
In-class arylcyclohexylamines cannot be substituted for methoxisopropamine without compromising analytical or experimental validity. Even minor structural modifications—such as the substitution of the amine moiety (e.g., isopropyl vs. ethyl or propyl)—result in quantifiable differences in NMDA receptor pharmacology, chromatographic behavior, and regulatory classification [1][2]. For example, MXiPr exhibits a distinct IC50 value for NMDAR blockade that differs from both methoxetamine and methoxpropamine, and its branched-chain amine imparts unique retention properties on biphenyl stationary phases [3][4]. These specific characteristics directly impact the accuracy of forensic identification, the reproducibility of in vitro assays, and the compliance of procurement with legal frameworks.
- [1] Kawamura M, et al. Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. J Pharmacol Sci. 2022;150(4):233-241. View Source
- [2] Irie T, et al. A potential of methoxpropamine to be a widespread recreational drug: it blocks NMDA receptors and inhibits NMDA receptor-mediated synaptic transmission in a brain preparation of mice. Forensic Toxicol. 2021;39(2):474-480. View Source
- [3] Kawamura M, et al. Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. J Pharmacol Sci. 2022;150(4):233-241. View Source
- [4] LCGC International. On the Surprising Retention Order of Ketamine Analogs Using a Biphenyl Stationary Phase. June 4, 2024. View Source
Quantitative Evidence Guide: Methoxisopropamine (MXiPr) Differentiation from Analogs
MXiPr NMDA Receptor Antagonism: IC50 Comparison to Methoxetamine and Deoxymethoxetamine
In a direct head-to-head patch-clamp study using NMDAR-expressing cartwheel interneurons of mice, MXiPr demonstrated an IC50 of 0.661 µM for NMDA receptor blockade. This potency is 26% lower than that of methoxetamine (MXE, IC50 = 0.524 µM) and 2.6% lower than deoxymethoxetamine (DMXE, IC50 = 0.679 µM) in the same assay system [1].
| Evidence Dimension | NMDA Receptor IC50 |
|---|---|
| Target Compound Data | 0.661 µM |
| Comparator Or Baseline | Methoxetamine (MXE) = 0.524 µM; Deoxymethoxetamine (DMXE) = 0.679 µM |
| Quantified Difference | MXiPr is 1.26-fold less potent than MXE, and 1.03-fold more potent than DMXE |
| Conditions | NMDAR-expressing cartwheel interneurons of mice; patch-clamp recordings |
Why This Matters
The specific IC50 value defines the potency range for in vitro NMDAR antagonism studies; selecting MXiPr over MXE provides a lower-potency tool compound, while it offers a marginal potency gain over DMXE for exploring structure-activity relationships.
MXiPr NMDA Receptor Antagonism: IC50 Comparison to Methoxpropamine (MXPr)
When compared to the structurally related analog methoxpropamine (MXPr, which features an n-propyl rather than isopropyl amine), MXiPr exhibits a lower IC50 for NMDA receptor blockade in mouse cartwheel interneurons. In cross-study analysis, MXiPr (IC50 = 0.661 µM) is 2.5-fold more potent than MXPr (IC50 = 1.647 µM) [1][2].
| Evidence Dimension | NMDA Receptor IC50 |
|---|---|
| Target Compound Data | 0.661 µM |
| Comparator Or Baseline | Methoxpropamine (MXPr) = 1.647 µM |
| Quantified Difference | MXiPr is 2.5-fold more potent than MXPr |
| Conditions | NMDAR-expressing cartwheel interneurons of mice; patch-clamp recordings (both studies employed comparable methods) |
Why This Matters
For researchers seeking a more potent tool within the 3-methoxyphenyl cyclohexanone series, MXiPr offers a substantial gain in potency over MXPr, making it a preferable choice for assays where higher NMDAR affinity is required.
MXiPr Distinctive Chromatographic Retention on Biphenyl Stationary Phases
MXiPr exhibits a unique, inverted retention order relative to its isomer methoxpropamine (MXPr) when analyzed on biphenyl stationary phases with methanol mobile phase. While branched-chain compounds typically elute before straight-chain analogs, the opposite order (MXiPr eluting later) was observed exclusively with biphenyl columns and methanol, a phenomenon not seen with C18 phases or acetonitrile mobile phases [1].
| Evidence Dimension | Chromatographic Retention Order |
|---|---|
| Target Compound Data | MXiPr elutes after MXPr (inverted retention order) |
| Comparator Or Baseline | Expected order: branched-chain (MXiPr) before straight-chain (MXPr) |
| Quantified Difference | Observed inversion: MXPr elutes before MXiPr under specific conditions |
| Conditions | Biphenyl stationary phase; methanol mobile phase; LC-MS |
Why This Matters
This unique chromatographic behavior is critical for forensic and toxicology laboratories developing robust LC-MS methods for the definitive identification of MXiPr, especially when isomeric differentiation from MXPr is required and standard MS fragmentation patterns are identical.
MXiPr Enhanced Ethanol Solubility vs. Methoxetamine
MXiPr hydrochloride demonstrates higher solubility in ethanol (20 mg/ml) compared to methoxetamine (MXE) hydrochloride, which is limited to 10 mg/ml under similar conditions . Both compounds show comparable solubility in DMSO (10 mg/ml) and PBS (2-5 mg/ml).
| Evidence Dimension | Solubility in Ethanol |
|---|---|
| Target Compound Data | 20 mg/ml |
| Comparator Or Baseline | Methoxetamine (MXE) = 10 mg/ml |
| Quantified Difference | MXiPr is 2-fold more soluble in ethanol than MXE |
| Conditions | Hydrochloride salt form; standard vendor-reported solubility data |
Why This Matters
The twofold higher ethanol solubility of MXiPr provides greater flexibility in preparing stock solutions or working dilutions for assays where ethanol is a preferred or required solvent, potentially reducing the need for DMSO and associated solvent toxicity concerns.
MXiPr Purity Specification and Regulatory Controlled Status
Commercially available MXiPr (hydrochloride) is supplied with a certified purity of ≥98%, suitable for use as an analytical reference standard . Procurement is subject to regulatory controls in multiple jurisdictions; for instance, it is designated as a controlled substance in Japan (prefectural level) and Germany, and many vendors require proof of licensed laboratory status [1].
| Evidence Dimension | Product Purity and Regulatory Status |
|---|---|
| Target Compound Data | ≥98% purity; controlled/restricted in multiple regions |
| Comparator Or Baseline | Typical research chemicals (variable purity; variable legal status) |
| Quantified Difference | Standardized reference grade purity; specific legal restrictions |
| Conditions | Hydrochloride salt; analytical standard grade |
Why This Matters
Procurement of MXiPr is contingent upon verifying both the certified purity for analytical accuracy and the regulatory compliance in the user’s jurisdiction. The controlled status distinguishes it from non-controlled arylcyclohexylamines and mandates careful sourcing from authorized vendors.
Key Application Scenarios for Methoxisopropamine (MXiPr) Based on Quantitative Evidence
Forensic Toxicology: Confirmatory Analysis and Isomer Differentiation
Forensic and toxicology laboratories require definitive identification of MXiPr in seized materials or biological samples. The unique inverted retention order on biphenyl LC columns with methanol mobile phase provides a critical orthogonal identification point beyond mass spectrometry, enabling reliable differentiation from the isomeric MXPr when MS fragmentation patterns are indistinguishable [1].
In Vitro NMDA Receptor Pharmacology: Potency-Tailored Tool Compound
Researchers investigating the structure-activity relationship of arylcyclohexylamine NMDAR antagonists can utilize MXiPr as a tool with an IC50 of 0.661 µM. This places its potency between the higher-affinity methoxetamine (0.524 µM) and the lower-affinity methoxpropamine (1.647 µM), offering a middle-ground option for dose-response studies or for comparing the effects of the isopropyl amine substitution [2][3].
Analytical Reference Standard for Method Validation and Quality Control
Analytical laboratories require certified reference materials for method development, validation, and routine quality control. MXiPr hydrochloride is available as a ≥98% pure reference standard, suitable for calibrating LC-MS or GC-MS instruments, preparing calibration curves, and spiking control samples to ensure accurate quantification in forensic casework .
Solvent Compatibility Studies in Formulation Research
For in vitro studies requiring ethanol as a solvent, MXiPr’s solubility of 20 mg/ml provides a practical advantage over methoxetamine (10 mg/ml). This higher ethanol solubility allows for the preparation of more concentrated stock solutions without resorting to DMSO, which may interfere with certain cell-based assays or receptor-binding studies .
- [1] LCGC International. On the Surprising Retention Order of Ketamine Analogs Using a Biphenyl Stationary Phase. June 4, 2024. View Source
- [2] Kawamura M, et al. Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. J Pharmacol Sci. 2022;150(4):233-241. View Source
- [3] Irie T, et al. A potential of methoxpropamine to be a widespread recreational drug: it blocks NMDA receptors and inhibits NMDA receptor-mediated synaptic transmission in a brain preparation of mice. Forensic Toxicol. 2021;39(2):474-480. View Source
Technical Documentation Hub
Structured technical reading across foundational, methodological, troubleshooting, and validation/comparative pathways. Use the hub when you need more detail before procurement.
Reviews
There are no reviews yet.